Iterum Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Iterum Therapeutics generated cash of -$39,330,000, which is less than the previous year. Cash used in financing activities reached the amount of $1,034,000 last year. Net change in cash is therefore -$15,021,000.
Cash Flow
| 2016 | -11.29M | 0 | 20.85M |
|---|---|---|---|
| 2017 | -30.60M | -31.58M | 45.86M |
| 2018 | -75.89M | -8.65M | 120.84M |
| 2019 | -78.88M | 40.10M | -974K |
| 2020 | -54.52M | -11K | 64.47M |
| 2021 | -15.84M | -54.59M | 83.12M |
| 2022 | -18.47M | 13.95M | -1.81M |
| 2023 | -39.33M | 23.33M | 1.03M |
ITRM Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 21.09M | 27.51M | 14.81M | 4.89M | 44.67M | 8.48M | 24.80M | 15.25M |
Operating activities | ||||||||
Net income | -38.37M | -44.43M | -91.56M | -52.00M | -103.13M | -77.05M | -29.40M | -13.46M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.75M | 1.8M | 2.10M | 161K | 152K | 136K | 65K | 0 |
Stock-based compensation expense | 784K | 4.75M | 4.31M | 2.75M | 2.17M | 0 | 392K | 348K |
| Deferred income tax benefit | 784K | 4.75M | 4.31M | 2.75M | 2.17M | 0 | 392K | 348K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.22M | 1.89M | 63K | -14.67M | 11.44M | 849K | 1.67M | 1.18M |
Cash generated by operating activities | -39.33M | -18.47M | -15.84M | -54.52M | -78.88M | -75.89M | -30.60M | -11.29M |
Investing activities | ||||||||
Purchases Of Investments | -41.17M | -45.70M | -67.03M | 0 | 0 | -96.49M | -53.27M | 0 |
Investments In Property Plant And Equipment | -13K | -62K | -61K | -11K | -24K | -90K | -812K | 0 |
Acquisitions Net | 0 | -14.01K | 54.53K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 23.33M | 13.95M | -54.59M | -11K | 40.10M | -8.65M | -31.58M | 0 |
Financing activities | ||||||||
Common Stock Issued | 1.03M | 433K | 89.64M | 69.96M | 3.03M | 74.15M | 45.86M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -2.25M | -6.51M | -6.23M | -1.03M | 0 | 0 | 0 |
Cash used in financing activities | 1.03M | -1.81M | 83.12M | 64.47M | -974K | 120.84M | 45.86M | 20.85M |
Net Change In Cash | -15.02M | -6.38M | 12.69M | 9.92M | -39.78M | 36.18M | -16.32M | 9.55M |
Cash at end of period | 6.07M | 21.12M | 27.51M | 14.81M | 4.89M | 44.67M | 8.48M | 24.80M |
| Data source | Data source | Data source | Data source | Data source | Data source |